2-(2-吡唑-1-基乙基)异吲哚-1,3-二酮 | 121751-71-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 中文名称: 2-(2-吡唑-1-基乙基)异吲哚-1,3-二酮
• 英文名称: 2-[2-(1H-pyrazol-1-yl)ethyl]-1H-isoindole-1,3(2H)-dione
• 英文别名: 2-[2-(pyrazol-1-yl)ethyl]isoindole-1,3-dione；N-(2-phthalimideethyl)pyrazole；1-(2-phthalimidoethyl)-1H-pyrazole；2-phthalimidoethylpyrazole；2-(2-(1H-Pyrazol-1-yl)ethyl)isoindoline-1,3-dione；2-(2-pyrazol-1-ylethyl)isoindole-1,3-dione
• CAS: 121751-71-1
• 化学式: C₁₃H₁₁N₃O₂
• 分子量: 241.249
• InChiKey: HJJKOBITSBBKBP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  55.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(2-吡唑-1-基乙基)异吲哚-1,3-二酮 在 盐酸 作用下， 以 水 为溶剂， 反应 8.0h， 以32%的产率得到2-吡唑-1-基乙胺
  参考文献：
  名称：

  低对称吡唑基三脚架四胺配体：金属络合物和配体分解反应†

  摘要：

  新的低对称吡唑基三脚架四胺配体2-（1 H-吡唑-1-基）-N，N-双（1 H-吡唑-1-基甲基）乙胺（bmpz）和2-（1 H-吡唑已经制备并表征了-1-基）-N- [2-（1 - H-吡唑-1-基）乙基] -N-（1H-吡唑-1-基甲基）乙胺和金属配合物。含有这些配体。[Co（bmpz）Cl] 2 [CoCl 4 ]·H 2 O，[Co（bmpz）MeCN]（ClO 4）2 ·0.13H 2 O，[Zn（bmpz）MeCN]（ClO 4）2 ·0.15H 2 O，[Zn（bepz）OH 2 ]（ClO 4） 2 ·0.5H 2 O和[（Co（bepz）Cl） 2 ] Cl 2 ·6H 2 O证实完整的三脚架配体与通过所有四个N原子的金属离子。但是，尝试制备含bmpz和bepz的Cu 2+络合物分别得到[Cu（ 7）Cl 2 ]·0.2H 2 O和[Cu（ 8）Cl 2 ]（ 7 = 1-（1

  DOI：

  10.1039/c2dt32200e
• 作为产物：
  描述：

  邻苯二甲酸亚胺 、 2-(1H-吡唑-1-基)乙醇 在 偶氮二甲酸二异丙酯 、 三苯基膦 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 生成 2-(2-吡唑-1-基乙基)异吲哚-1,3-二酮
  参考文献：
  名称：

  [EN] CEPHEM COMPOUNDS
  [FR] COMPOSES CEPHEMES

  摘要：

  本发明涉及一种化合物，其化学式为[I]：其中R1是可能具有适当取代基的低碳烷基，R2是氨基、保护氨基或胍基，R3是羧基或保护羧基，R4是氨基或保护氨基，A是低碳烷基，或其在药学上可接受的盐，一种制备化合物[I]的方法，以及包含化合物[I]与药学上可接受的载体混合的药物组合物。

  公开号：

  WO2004101571A1

文献信息

• [EN] BENZOXAZOLE ACETONITRILES<br/>[FR] BENZOXAZOLE ACETONITRILES
  申请人：APPLIED RESEARCH SYSTEMS

  公开号：WO2005026159A1

  公开（公告）日：2005-03-24

  The present invention is related to benzoxazole acetonitriles as well as to pharmaceutical formulations containing such benzoxazole acetonitriles pof formula (I). Said benzoxazole acetonitriles are useful in the treatment of metabolic disorders mediated by insulin resistance or hyperglycernia, comprising diabetes type II, inadequate glucose tolerance, insulin resistance, obesity, polycystic ovary syndrome (PCOS). The present invention is furthermore related to methods of preparing benzoxazole acetonitriles (I). A is a pyrimidinyl.L is a secondary or tertiary amino group, or a 3-8 membered heterocycloalkyl, containing at least one heteroatom. selected from N, O, S or L is an acylarnino moiety.R1 is selected from the group comprising or consisting of hydrogen, sulfonyl, amino, CiC6-alkYl, C2-C6-alkenYl, C2-C6-alkynyl or Cl-C6-alkoxy, aryl, halogen, carboxy,aminocarbonyl, cyano or hydroxy.

  本发明涉及苯并噁唑乙腈，以及含有该苯并噁唑乙腈的药物配方（I）的制备方法。所述苯并噁唑乙腈在治疗由胰岛素抵抗或高甘油三酯引起的代谢紊乱方面具有用途，包括糖尿病II型、葡萄糖耐量不佳、胰岛素抵抗、肥胖、多囊卵巢综合征（PCOS）。A是嘧啶基。L是次级或三级氨基团，或者是含有至少一个来自N、O、S的杂原子的3-8环杂环烷基。R1选择自氢、磺酰基、氨基、CiC6-烷基、C2-C6-烯基、C2-C6-炔基、Cl-C6-烷氧基、芳基、卤素、羧基、氨基羰基、氰基或羟基。
• Rhenium(<scp>v</scp>) oxocomplexes with novel pyrazolyl-based N₄- and N₃S-donor chelators
  作者：Carolina Moura、Rute F. Vítor、Leonor Maria、António Paulo、Isabel C. Santos、Isabel Santos

  DOI：10.1039/b611034g

  日期：——

  The novel pyrazolyl-based ligands 3,5-Me2pz(CH2)2NH(CH2)2NH(CH2)2NH2 (1) and pz*(CH2)2NH-Gly-CH2STrit (pz* = pz (8), 3,5-Me2pz (9), 4-(EtOOC)CH2-3,5-Me2pz (10)) were synthesized, and their suitability to stabilize Re(V) oxocomplexes was evaluated using different starting materials, namely (NBu4)[ReOCl4], [ReOCl3(PPh3)2] and trans-[ReO2(py)4]Cl. Compound 1 reacts with trans-[ReO2(py)4]Cl yielding the cationic compound [ReO(OMe)3,5-Me2pz(CH2)2N(CH2)2NH(CH2)2NH2}](BPh4) (11) in a low isolated yield. In contrast, the neutral complexes [ReOpz*(CH2)2NH-Gly-CH2S}] (pz* = pz (12), 3,5-Me2pz (13), 4-(EtOOCCH2)-3,5-Me2pz (14)) were synthesized almost quantitatively by reacting [ReOCl3(PPh3)2] or (NBu4)[ReOCl4] with the trityl-protected chelators 8–10. The X-ray diffraction analysis of 11 and 13 confirmed the tetradentate coordination mode of the respective ancillary ligands. In 11 the monoanionic chelator coordinates to the metal through four nitrogen atoms, while in 13 the chelator is trianionic, coordinating to the metal through three nitrogens and one sulfur atom. Solution NMR studies of 12–14, including two-dimensional NMR techniques (1H COSY and 1H/13C HSQC), confirmed that the N3S coordination mode of the chelators is retained in solution. Unlike 11, complexes 12–14 may be considered relevant in the development of radiopharmaceuticals, as further corroborated by the synthesis of the congener [99mTcOpz(CH2)2-NH-Gly-CH2S}] (12a). This radioactive compound was obtained from 99mTcO4− in aqueous medium, in almost quantitative yield and with high specific activity and radiochemical purity.

  合成了新型的以吡唑基为基础的配体3,5-Me2pz(CH2)2NH(CH2)2NH(CH2)2NH2 (1)和pz*(CH2)2NH-Gly-CH2STrit（pz* = pz (8)，3,5-Me2pz (9)，4-(EtOOC)CH2-3,5-Me2pz (10)），并评估了它们稳定Re(V)氧化络合物的适用性，使用的起始材料分别为(NBu4)[ReOCl4]、[ReOCl3(PPh3)2] 和 trans-[ReO2(py)4]Cl。化合物1与trans-[ReO2(py)4]Cl反应，生成阳离子化合物[ReO(OMe)3,5-Me2pz(CH2)2N(CH2)2NH(CH2)2NH2}](BPh4) (11)，其孤立产率较低。相比之下，几乎定量合成了中性复合物[ReOpz*(CH2)2NH-Gly-CH2S}] (pz* = pz (12)，3,5-Me2pz (13)，4-(EtOOCCH2)-3,5-Me2pz (14))，通过将[ReOCl3(PPh3)2]或(NBu4)[ReOCl4]与三苯基保护的螯合剂8–10反应。对11和13的X射线衍射分析确认了各自辅助配体的四齿配位模式。在11中，单阴离子螯合剂通过四个氮原子与金属配位，而在13中，螯合剂是三阴离子，通过三个氮和一个硫原子与金属配位。对12–14的溶液NMR研究，包括二维NMR技术（1H COSY和1H/13C HSQC），确认了螯合剂的N3S配位模式在溶液中的保留。与11不同，复合物12–14被认为在放射药物开发中具有相关性，进一步通过合成同类物[99mTcOpz(CH2)2-NH-Gly-CH2S}] (12a)得到了印证。该放射性化合物在水相中从99mTcO4−获得，几乎定量收率，并具有高特异活性和放射化学纯度。
• Cephem compounds
  申请人：Yamanaka Toshio

  公开号：US20050004094A1

  公开（公告）日：2005-01-06

  The present invention relates to a compound of the formula [I]: wherein R 1 is lower alkyl which may have suitable substituent(s), R 2 is amino, protected amino or guanidino, R 3 is carboxy or protected carboxy, R 4 is amino or protected amino, and A is lower alkylene, or a pharmaceutically acceptable salt thereof, a process for preparing a compound of the formula [I], and a pharmaceutical composition comprising a compound of the formula [I] in admixture with a pharmaceutically acceptable carrier.

  本发明涉及一种化合物，其化学式为[I]，其中R1是较低的烷基，可以具有适当的取代基；R2是氨基，保护氨基或鸟氨酸基；R3是羧基或保护羧基；R4是氨基或保护氨基，A是较低的烷基烯，或其药学上可接受的盐，以及制备化合物[I]的方法和包含化合物[I]的药物组合物与药学上可接受的载体混合的药物组合物。
• Benzoxazole acetonitriles
  申请人：Schwarz Matthias

  公开号：US20070185104A1

  公开（公告）日：2007-08-09

  The present invention is related to benzoxazole acetonitriles as well as to pharmaceutical formulations containing such benzoxazole acetonitriles pof formula (I). Said benzoxazole acetonitriles are useful in the treatment of metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type II, inadequate glucose tolerance, insulin resistance, obesity, polycystic ovary syndrome (PCOS). The present invention is furthermore related to methods of preparing benzoxazole acetonitriles (I). A is a pyrimidinyl.L is a secondary or tertiary amino group, or a 3-8 membered heterocycloalkyl, containing at least one heteroatom. selected from N, O, S or L is an acylamino moiety. R 1 is selected from the group comprising or consisting of hydrogen, sulfonyl, amino, C 1 C 6 -alkYl, C 2 -C 6 -alkenYl, C 2 -C 6 -alkynyl or C 1 -C 6 -alkoxy, aryl, halogen, carboxy, aminocarbonyl, cyano or hydroxy.

  本发明涉及苯并噁唑乙腈，以及含有该类苯并噁唑乙腈的制药配方(I)。所述苯并噁唑乙腈在治疗胰岛素抵抗或高血糖介导的代谢性疾病方面具有用途，包括2型糖尿病、不足的葡萄糖耐受性、胰岛素抵抗、肥胖症、多囊卵巢综合症（PCOS）。本发明还涉及制备苯并噁唑乙腈(I)的方法。其中A是吡咯啉基。L是一个次要或三级氨基团，或一个3-8个成员的杂环烷基，其中至少包含一个杂原子，选择自N、O、S，或L是一个酰胺基团。R1选择自氢、磺酰基、氨基、C1-C6-烷基、C2-C6-烯基、C2-C6-炔基或C1-C6-烷氧基、芳基、卤素、羧基、氨基甲酰基、氰基或羟基组成的群。
• Cinnamic Acid Amide Derivative
  申请人：NIPPON ZOKI PHARMACEUTICAL CO., LTD.

  公开号：US20150322024A1

  公开（公告）日：2015-11-12

  The present invention provides a cinnamic acid amide derivative having an excellent analgesic action. The cinnamic acid amide derivative of the present invention is a compound showing excellent analgesic actions to not only a nociceptive pain model animal but also a neuropathic pain model animal, which is very useful as an agent for treating various pain diseases showing acute or chronic pains or neuropathic pains.

  本发明提供一种具有出色镇痛作用的肉桂酸酰胺衍生物。本发明的肉桂酸酰胺衍生物是一种化合物，不仅对伤害性疼痛模型动物，而且对神经病理性疼痛模型动物显示出出色的镇痛作用，非常适用于治疗各种急性或慢性疼痛或神经病理性疼痛的药剂。